SR604 for hemophilia a

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 May 2024: Trial started, NCT07644832
  2. 12 Jun 2026: Trial registered, NCT07644832

The trials

NCT07644832: An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

State
Under way
Phase
Phase 1 and Phase 2
People
76 planned
Started
31 May 2024
Primary completion
31 Dec 2026
Arms
Part A: Dose escalation trial consists of 6 cohorts, Part B: Multiple-dose exploratory efficacy trial consists of 2 cohorts, Part C: Multiple-dose exploratory efficacy trial consists of 3 cohorts
Results
None posted
  1. 31 May 2024: Trial started
  2. 12 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.